Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Travoprost/Timolol Combination May Increase Compliance Among Patients With Glaucoma: Presented at COS By Louise Gagnon TORONTO -- June 25, 2009 -- The use of an agent that combines 2 glaucoma medications produces increased compliance among patients with glaucoma, according to a study presented here at the 72nd Annual Meeting and Exhibition of the Canadian Ophthalmological Society (COS). The availability of 2 medications in 1 drug encourages better adherence to drug therapy, said Lesya Shuba, MD, Department of Ophthalmology and Visual Sciences, Dalhousie University, Halifax, Nova Scotia, on June 22. The prospective, multicentre, open-label DuoTrav Adjunctive Therapy Evaluation (DATE) study recruited 365 patients aged >=18 years with primary open-angle glaucoma or ocular hypertension who made a modification to their medical therapy based on the judgment of the study investigators. The investigators documented intraocular pressure (IOP) at baseline and after 30 days with travoprost 0.004%/timolol 0.5% taken once daily. Patients were divided according to their previous use of therapy, with 36 patients having used beta-blocker monotherapy, 276 receiving prostaglandin analogue (PGA) monotherapy, 44 receiving a fixed combination of latanoprost plus timolol, and 10 receiving a fixed combination of brimonidine plus timolol. The researchers observed significant drops in IOP when patients switched to travoprost/timolol: 20.9 +- 3.3 to 16.4 +- 3.6 mm Hg (P < .0001) in the beta-blocker group; 22.3 +- 4.8 to 17.6 +- 3.9 mm Hg (P < .0001) in the PGA group; 21.9 +- 6.4 to 17.2 +- 3.8 mm Hg (P < .0001) in the latanoprost/timolol group; and 19.9 +- 5.8 to 16.1 +- 5.6 mm Hg (P = .001) in the brimonidine/timolol group. Most patients (52%) said that once-daily morning dosing of travoprost/timolol was much more or somewhat more convenient. Forty-one percent said the convenience was the same as with their previous regimen. "Patients said that they were at least as satisfied or more satisfied with the morning use of medications," said Dr. Shuba. In addition, 31% of patients indicated that they missed their dose far fewer or somewhat fewer times after switching therapy to travoprost/timolol, and 66% said their compliance did not change. The availability of 2 medications in 1 preparation also reduces the likelihood of adverse events, according to Dr. Shuba. Regardless of the previous therapy that patients followed, patients experienced further decreases in IOP with a fixed-combination therapy of travoprost 0.004%/timolol 0.5%, Dr. Shuba concluded. Funding for this study was provided by Alcon Canada Inc. [Presentation title: Observational Study of Combination Travoprost 0.004%/Timolol 0.5% in Glaucoma Patients. Abstract 1] E-mail this page to a friend or colleague! To print, use this version